263409-81-0

Basic information

• Product Name: 2-(4-Fluorophenoxy)-1-ethanamine(HCl)
• Synonyms: 2-(4-Fluorophenoxy)-1-ethanamine(HCl)
• CAS NO: 263409-81-0
• Molecular Formula: C8H11ClFNO
• Molecular Weight: 191.63
• Mol File: 263409-81-0.mol

Chemical Properties

• Melting Point: 213-216℃
• Boiling Point: 282.8oC at 760 mmHg
• Flash Point: 124.8oC
• Appearance: /
• Vapor Pressure: 0.00251mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Sensitive: Hygroscopic
• CAS DataBase Reference: 2-(4-Fluorophenoxy)-1-ethanamine(HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Fluorophenoxy)-1-ethanamine(HCl)(263409-81-0)
• EPA Substance Registry System: 2-(4-Fluorophenoxy)-1-ethanamine(HCl)(263409-81-0)

Safety Data

• Hazardous Substances Data: 263409-81-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Fluorophenoxy)-1-ethanamine(HCl) is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, featuring a fluorophenoxy group, can contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Industry:
In the chemical industry, 2-(4-Fluorophenoxy)-1-ethanamine(HCl) is utilized as a precursor in the production of specialty chemicals. Its versatility in chemical reactions allows for the creation of a range of products with diverse applications.
Used in Research and Development:
2-(4-Fluorophenoxy)-1-ethanamine(HCl) is employed as a research compound in the exploration of new drug candidates and chemical entities. Its potential role in medicinal chemistry makes it a valuable tool for scientists working on the discovery and optimization of novel therapeutic agents.

InChI:InChI=1/C8H10FNO.ClH/c9-7-1-3-8(4-2-7)11-6-5-10;/h1-4H,5-6,10H2;1H

Upstream product

• 24115-20-6 2-(4-fluorophenoxy)acetonitrile 
• 371-41-5 4-Fluorophenol 
• 332-48-9 2-(4-fluorophenoxy)-ethylbromide 
• 263409-78-5 tert-butyl (2-(4-fluorophenoxy)ethyl)carbamate 

Relevant articles and documents

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

THIAZOLE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides thiazole derivatives as Stearoyl CoA Desaturase (SCD) inhibitors. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase

Development of a scalable synthesis of a nonbasic inhibitor of the serine protease tryptase

A chromatography-free process for the synthesis of a bis(benzimidazole)difluoromethane inhibitor of the serine protease tryptase is described. This synthesis features the introduction of the gem-difluoro moiety using the electrophilic fluorinating reagent N-fluoro-bis(phenylsulfonimide) as well as the stepwise introduction of both benzimidazole rings. A protocol for the destruction of reactive, process-related substances produced in the synthesis is also presented.

ETHER DERIVATIVE

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES

This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excelle